ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

pfizer europe ma eeig - inotuzumab ozogamicin - leucemia limfoblastică limfoblastică a celulelor precursoare - agenți antineoplazici - besponsa este indicat în monoterapie pentru tratamentul pacienților adulți cu recidivat sau refractar cd22-pozitiv cu celule b precursoare leucemie limfoblastică acută (all). pacienți adulți cu cromozom philadelphia pozitiv (ph+) recidivat sau refractar cu celule b precursoare toate ar fi eșuat tratamentul cu cel puțin 1 inhibitor de tirozin kinaza (tki).

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

intervet international b.v. - fluralaner - ectoparaciticide, insecticide și repellente - pui - tratamentul păsărilor acarianul roșu (dermanyssus gallinae) infestare în puicuțe, crescători de animale și strat de găini.

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - carcinom, pulmonar non-celulă mică - agenți antineoplazici - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

krka d.d. - pemetrexed disodic - carcinoma, non-small-cell lung; mesothelioma - agenți antineoplazici - pleural malign mesotheliomapemetrexed krka în asociere cu cisplatină este indicat pentru tratamentul de chimioterapie la pacienți netratați anterior cu mezoteliom pleural malign nerezecabil. non-pulmonar cu celule mici cancerpemetrexed krka în asociere cu cisplatină este indicat pentru tratamentul de primă linie al pacienților cu local avansat sau metastatic cu celule non-mici cancer pulmonar altul decât predominant tipul histologic cu celule scuamoase. pemetrexed krka este indicat în monoterapie pentru tratamentul de întreținere de la nivel local avansat sau metastatic cu celule non-mici cancer pulmonar altul decât predominant tipul histologic cu celule scuamoase la pacienții a căror boală nu a progresat imediat după chimioterapie pe bază de platină. pemetrexed krka este indicat ca monoterapie pentru cea de-a doua linie de tratament a pacienților cu local avansat sau metastatic cu celule non-mici cancer pulmonar altul decât predominant tipul histologic cu celule scuamoase.

রুমানিয়া - রোমানীয় - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

arena group s.a. - romania - clopidogrelum - compr. film. - 75mg - antitrombotice antiagregante plachetare

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - carcinom, celule scuamoase - agenți antineoplazici - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - carcinom, pulmonar non-celulă mică - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

mylan ireland limited - trioxid de arsen - leucemie, promielocitară, acută - agenți antineoplazici - trioxid de arsen mylan este indicat pentru inducerea remisiunii și consolidare la pacienții adulți cu:- nou-diagnosticate de scăzut pentru risc intermediar leucemie acută promielocitară (lap) (celule albe din sânge, ≤ 10 x 103/µl), în combinație cu toate trans acid retinoic (atra)- recidivat/refractar leucemie acută promielocitară (lap) (tratamentul anterior trebuie să fi inclus un retinoid și chimioterapie), caracterizată prin prezența t(15;17) translocație și/sau prezența de leucemie promielocitară/retinoic acid alfa receptorilor (pml/rar-alfa) gene. rata de răspuns de alte leucemie mieloidă acută subtipuri de trioxid de arsen nu a beenexamined.

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - trioxid de arsen - leucemie, promielocitară, acută - agenți antineoplazici - arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with:newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 10³/μl) in combination with all-trans-retinoic acid (atra)relapsed/refractory apl (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rarα) gene. rata de răspuns de alte leucemie mieloidă acută subtipuri de trioxid de arsen nu a fost examinată.

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

alnylam netherlands b.v. - lumasiran sodium - hyperoxaluria, primary - alte medicamente pentru tractul digestiv și metabolism, - treatment of primary hyperoxaluria type 1 (ph1) in all age groups.